More Bad Safety News for Xeljanz Another analysis of the mandatory postmarketing safety study for tofacitinib (Xeljanz) has confirmed what most observers expected: that rates of infection with the drug in RA are higher than with TNF inhibitors. https://t.co/iCrEofMjBR https://t.co/wAr1AuNGUw